Cannabis Therapy Helped 91.5% of Nerve Pain Patients—and a Novel Biomarker Tracked Anxiety, Not Pain

Prospective cohort study. 200 adults with electrodiagnostically confirmed neuropathic pain receiving cannabis therapy for 48 months. Assessments: NRS (pain), GAD-7 (anxiety), Biowell UPE measurements. Correlation analyses, ROC analysis, and mixed-effects modeling for UPE specificity.

The 91.5% response rate for neuropathic pain over 4 years is one of the strongest real-world outcomes in the cannabis pain literature—particularly given RTHC-00170's finding that neuropathic pain patients use cannabis more intensively than other pain patients and RTHC-00200's identification of CBG as a potential nerve pain treatment. The biomarker work is more exploratory but points toward objective measurement tools for conditions that currently rely entirely on self-report.

The 91.5% neuropathic pain response rate contrasts sharply with RTHC-00182's null result for CBD in knee osteoarthritis and RTHC-00158's mixed results in cancer symptoms. This reinforces the emerging pattern: cannabis appears most effective for neuropathic pain specifically, less effective for other pain types. The anxiety-specific biomarker finding connects to RTHC-00196's evidence that higher CBD doses improved anxiety in cancer patients—cannabis's anxiety-reducing effects may be a distinct therapeutic pathway from its analgesic effects.

No control group or placebo arm—the 91.5% response rate could partly reflect placebo effects, regression to the mean, or other treatments. UPE/Biowell is a novel and controversial measurement technology with limited validation. All patients had neuropathic pain—results don't apply to other pain types. Self-selected patients receiving cannabis therapy may be predisposed to report improvement. Israeli medical cannabis program context may differ from other healthcare systems.